MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/sj.npp.1301093

Медицинская библиотека · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2006

Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.

Raskind Murray A, Burke Brianna L, Crites Norman J, Tapp Andre M, Rasmussen Dennis D

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАПеревод пока не подготовлен

Аннотация

The atypical antipsychotic drug olanzapine increases body weight and visceral adiposity in schizophrenia. In rats, aging-associated increased body weight and visceral adiposity are reversed by administration of the pineal hormone melatonin. We asked if melatonin similarly would reverse olanzapine-induced increased weight and visceral adiposity in rats. Four groups (n=11/group) of female rats (240-250 g) were treated for 8 weeks with olanzapine, melatonin, olanzapine+melatonin, or vehicle alone in drinking water. Body weight and food and water consumption were determined weekly, locomotor activity at weeks 3 and 6, and nocturnal plasma melatonin concentration at week 7. At week 8, the rats were killed and visceral (perirenal, retroperitoneal, omental, and mesenteric) fat pads dissected and weighed. Olanzapine treatment reduced nocturnal plasma melatonin by 55% (p<0.001), which was restored to control levels by olanzapine+melatonin. Body weight increased 18% in rats treated with olanzapine alone, but only 10% with olanzapine+melatonin, 5% with melatonin alone, and 7% with vehicle control. Body weight and visceral fat pad weight increases in rats treated with olanzapine alone were greater than in each of the other three groups (all p<0.01), which were not significantly different. These results suggest that olanzapine-induced increases in body weight and visceral adiposity may be at least in part secondary to olanzapine-induced reduction of plasma melatonin levels, and that melatonin may be useful for the management of olanzapine-induced weight gain in humans.

Для цитирования: Raskind Murray A, Burke Brianna L, Crites Norman J, Tapp Andre M, Rasmussen Dennis D. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006. DOI: 10.1038/sj.npp.1301093.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.